LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells
2006

LMP-420 Reduces HIV-1 and Mycobacterium tuberculosis Replication

publication Evidence: moderate

Author Information

Author(s): Haraguchi Soichi, Day Noorbibi K, Kamchaisatian Wasu, Beigier-Pompadre Macarena, Stenger Steffen, Tangsinmankong Nutthapong, Sleasman John W, Pizzo Salvatore V, Cianciolo George J

Primary Institution: Department of Pediatrics, University of South Florida

Hypothesis

Can LMP-420, a small-molecule inhibitor of TNF-alpha, block the replication of HIV-1 and Mycobacterium tuberculosis?

Conclusion

LMP-420 effectively inhibits the replication of both HIV-1 and Mycobacterium tuberculosis in human cells.

Supporting Evidence

  • LMP-420 alone inhibited HIV replication over 7 days with an IC50 of ~300 nM.
  • Combination of LMP-420 with AZT doubled the level of HIV inhibition observed with AZT alone.
  • LMP-420 alone inhibited the replication of virulent M. Tb by >80%.

Takeaway

LMP-420 is a new drug that helps stop two bad germs, HIV and tuberculosis, from making more copies of themselves in our bodies.

Methodology

LMP-420 was tested on HIV-1 infected human peripheral blood mononuclear cells and Mycobacterium tuberculosis-infected human alveolar macrophages to measure viral and bacterial replication.

Limitations

The study is limited to in vitro results and does not address potential clinical outcomes or long-term effects.

Digital Object Identifier (DOI)

10.1186/1742-6405-3-8

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication